Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 670 across all filing types
Latest filing 2020-10-28 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
关于变更公司注册资本、公司类型、修订《公司章程》及办理工商变更登记的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from a company about changes to its registered capital, company type, and amendments to its Articles of Association (company charter). It includes details about the approval from the China Securities Regulatory Commission for the company's initial public offering, changes in share capital, and revisions to the company charter clauses. The document also mentions the upcoming shareholder meeting to approve these changes. There are no financial statements or detailed financial performance data present, nor is this a transcript, audit report, or earnings release. The document is a formal announcement of corporate governance changes and capital structure updates, specifically about the change in registered capital and company type, and the revision of the company charter. This fits best under the category of Share Issue/Capital Change (SHA), as it concerns changes in registered capital and company type due to an IPO and related corporate amendments.
2020-10-28 Chinese
风险提示公告
Regulatory Filings Classification · 95% confidence The document is a risk warning announcement from 奥锐特药业股份有限公司 regarding abnormal stock price fluctuations and related risk factors such as international trade environment and exchange rate risks. It does not contain financial statements, management discussion, or detailed financial data. It is a regulatory announcement to inform investors about stock price volatility and associated risks, typical of a Regulatory Filings (RNS) category. The document length is short (1136 characters) and it is not a report or presentation but a formal disclosure to comply with stock exchange rules.
2020-10-20 Chinese
控股股东浙江桐本投资有限公司关于奥锐特股票交易异常波动征询函的回函
Regulatory Filings Classification · 95% confidence The document is a response letter to an inquiry about abnormal stock trading fluctuations. It states that the company has no undisclosed major information affecting stock price volatility. The content is a regulatory communication addressing stock trading concerns, not a financial report, management change, or other specific filings. The document is short and serves as a formal reply to a regulatory inquiry, fitting best under Regulatory Filings (RNS).
2020-10-19 Chinese
药业股份有限公司股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock price fluctuations of 奥锐特药业股份有限公司 (Aoruite Pharmaceutical Co., Ltd.) on specific trading days. It details the company's investigation into the cause of the price movements, confirms no undisclosed material information exists, and provides risk warnings to investors. The document is short (1318 characters) and focuses on stock trading irregularities rather than financial results, management changes, or other report types. It does not contain financial statements or detailed financial data. This type of announcement fits the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2020-10-19 Chinese
实际控制人彭志恩关于奥锐特股票交易异常波动征询函的回函
Regulatory Filings Classification · 95% confidence The document is a response letter from the actual controller of the company addressing an inquiry about abnormal stock price fluctuations. It explicitly states that no undisclosed major events affecting stock price have occurred. The document is short (325 characters) and is a regulatory communication rather than a financial report or announcement of a meeting, voting, or capital changes. It does not contain financial data, management changes, or legal proceedings. It fits best as a Regulatory Filing (RNS) because it is a formal regulatory response to a stock exchange inquiry about trading abnormalities.
2020-10-19 Chinese
控股股东浙江桐本投资有限公司关于奥锐特药业股份有限公司股票交易异常波动的征询函的回函
Regulatory Filings Classification · 95% confidence The document is a response letter to an inquiry about abnormal stock trading fluctuations. It states that the company has no undisclosed major events affecting stock price. The content is a regulatory response to a stock exchange inquiry rather than a financial report or announcement of a meeting or vote. It is short (311 characters) and does not contain financial data or detailed report content. Therefore, it fits best under Regulatory Filings (RNS) as a compliance document responding to a regulatory inquiry.
2020-09-25 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.